Andrea De Giglio

机构：Azienda USL di Bologna, University of Bologna · ORCID：0000-0002-0731-5721

发表论文 165 篇 · 总被引 3941 次 · h-index 31

代表论文

• Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis (2025 · The Lancet Oncology · 被引 44)
• First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study (2025 · The Lancet Oncology · 被引 11)
• Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% (2025 · ESMO Open · 被引 4)
• Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry (2025 · Journal for ImmunoTherapy of Cancer · 被引 2)
• Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity (2025 · Lung Cancer · 被引 1)
• P2.06.92 Host-Derived Biomarkers of Inflammation and Body Composition Predict Immunotherapy Outcomes in Advanced NSCLC (2025 · Journal of Thoracic Oncology · 被引 1)